Appili Therapeutics Inc., an anti-infective pharmaceutical development company, announced today that Kimberly Stephens, CPA, has joined the company as Chief Financial Officer. Ms. Stephens will be providing key financial and operational leadership to Appili to help drive its growth.
"We are pleased to welcome Ms. Stephens to the Appili executive management team,” said Kevin Sullivan, CEO of Appili Therapeutics. “Her significant financial expertise and insight into the biopharmaceutical industry will bolster our growing scientific pipeline as we take our first product, a taste-masked treatment for Clostridium difficile infection, into clinical trials.”
“With our first clinical trial on the horizon, it’s an exciting time to be joining Appili and I look forward to being a key contributor to the company’s future growth and acquisition success,” said Ms. Stephens. “I am impressed by Appili’s strategic focus on treating infectious diseases, and it is my privilege to join such a dynamic team of dedicated professionals.”
Ms. Stephens brings over 15 years of financial management experience in senior financial positions with private and public companies. Most recently, she served as CFO of Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) from 2011-2016, where she managed the raising of more than $40 million through equity financings and government grants. Prior to joining Immunovaccine Inc., Ms. Stephens served as director of finance for the Canadian subsidiary of Germanischer Lloyd. She has also been the director of finance for SolutionInc, and started her career as an audit manager in the assurance and advisory group at PwC. Ms. Stephens holds a bachelor of commerce degree from Mount Allison University and is a chartered professional accountant (CPA).
Ms. Stephens will continue to serve Immunovaccine as Chief Financial Officer through December 2016 while the company conducts its ongoing process of identifying and transitioning her successor.
About Appili Therapeutics
Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501, a taste-masked treatment for Clostridium difficile infection, has been granted orphan drug designation by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit www.AppiliTherapeutics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003005389/en/Business Wire
Last updated on: 03/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.